Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

3 Apr 2018

Abstract excerpt

BACKGROUND: Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard therapy for cancer patients with activating BRAF mutations. However, the anti-tumorigenic effect and clinical benefit are only transient, and tumors are prone to treatment resistance and relapse. To elucidate mechanistic insights into drug resistance, we have established an in vitro cellular model of MAPK inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways
Share to Protein Tyrosine Phosphatases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29615030
DOI: 10.1186/s12918-018-0554-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaPMID 29615030Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF <sup>V600</sup> melanomaSemantic proximity Read ↗

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance.Semantic proximity Read ↗

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibitionSemantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistanceSemantic proximity Read ↗

Metabolic rewiring in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.